Phenotypes of refractory/severe asthma

Paediatric Respiratory Reviews

Volumn 12, Issue 3, 2011, Pages 177-181

  Bush, Andrew ^a   Fleming, Louise ^b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Airway inflammation; Atopy; Bronchoscopy; Eosinophil; IgE; Induced sputum

Indexed keywords

CORTICOSTEROID; TRIAMCINOLONE;

ANTIFUNGAL SUSCEPTIBILITY; APOPTOSIS; ASTHMA; BRONCHOSCOPY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; HUMAN; INFLAMMATION; NEUTROPHIL; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; SYMPTOM; TRANSBRONCHIAL BIOPSY;

ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHOSCOPY; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; PHENOTYPE; RESPIRATORY SOUNDS; SEVERITY OF ILLNESS INDEX;

EID: 79959731559     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2011.01.003     Document Type: Review

References (60)

1. Brand P.L., Baraldi E., Bisgaard H., Boner A.L., Castro-Rodriguez J.A., Custovic A., de Blic J., de Jongste J.C., Eber E., Everard M.L., Frey U., Gappa M., Garcia-Marcos L., Grigg J., Lenney W., Le Souëf P., McKenzie S., Merkus P.J., Midulla F., Paton J.Y., Piacentini G., Pohunek P., Rossi G.A., Seddon P., Silverman M., Sly P.D., Stick S., Valiulis A., van Aalderen W.M., Wildhaber J.H., Wennergren G., Wilson N., Zivkovic Z., Bush A. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J. 2008, 32:1096-1110.
2. Schultz A., Devadason S.G., Savenije O.E., Sly P.D., Le Souëf P.N., Brand P.L. The transient value of classifying preschool wheeze into episodic viral wheeze and multiple trigger wheeze. Acta Paediatr. 2010, 99:56-60.
3. Major RH. Classic descriptions of disease. Springfield: Thomas, 3rd Edition, 1948.
4. Henderson J., Granell R., Heron J., Sherriff A., Simpson A., Woodcock A., Strachan D.P., Shaheen S.O., Sterne J.A. Associations of wheezing phenotypes in the first 6 years of life with atopy, lung function and airway responsiveness in mid-childhood. Thorax 2008, 63:974-980.
5. Smith J.A., Drake R., Simpson A., Woodcock A., Pickles A., Custovic A. Dimensions of respiratory symptoms in preschool children: population-based birth cohort study. Am J Respir Crit Care Med 2008, 177:1358-1363.
6. Spycher B.D., Silverman M., Brooke A.M., Minder C.E., Kuehni C.E. Distinguishing phenotypes of childhood wheeze and cough using latent class analysis. Eur Respir J. 2008, 31:974-981.
7. Auffray C., Adcock I.M., Chung K.F., Djukanovic R., Pison C., Sterk P.J. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010, 137:1410-1416.
8. Hall I.P., Blakey J.D. Genetic association studies in Thorax. Thorax. 2005, 60:357-359.
9. Simpson J.L., Scott R., Boyle M.J., Gibson P.G. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006, 11:54-61.
10. Lex C., Ferreira F., Zacharasiewicz A., Nicholson A.G., Haslam P.L., Wilson N.M., Hansel T.T., Payne D.N., Bush A. Airway eosinophilia in children with severe asthma: Predictive values of non-invasive tests. Am J Respir Crit Care Med 2006, 174:1286-1291.
11. Leckie M.J., ten Brinke A., Khan J., Diamant Z., O'Connor B.J., Walls C.M., Mathur A.K., Cowley H.C., Chung K.F., Djukanovic R., Hansel T.T., Holgate S.T., Sterk P.J., Barnes P.J. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000, 356:2144-2148.
12. Flood-Page P.T., Menzies-Gow A.N., Kay A.B., Robinson D.S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003, 167:199-204.
13. van den Toorn L.M., Overbeek S.E., de Jongste J.C., Leman K., Hoogsteden H.C., Prins J.B. Airway inflammation is present during clinical remission of atopic asthma. Am J Respir Crit Care Med. 2001, 164:2107-2113.
14. Kraft M., Djukanovic R., Wilson S., Holgate S.T., Martin R.J. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med. 1996, 154:1505-1510.
15. Sutherland E.R., Martin R.J., Bowler R.P., Zhang Y., Rex M.D., Kraft M. Physiologic correlates of distal lung inflammation in asthma. J Allergy Clin Immunol. 2004, 113:1046-1050.
16. Kraft M., Martin R.J., Wilson S., Djukanovic R., Holgate S.T. Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma. Am J Respir Crit Care Med. 1999, 159:228-234.
17. Whitehead B., Scott J.P., Helms P., Malone M., Macrae D., Higenbottam T.W., Smyth R.L., Wallwork J., Elliott M., de Leval M. Technique and use of transbronchial biopsy in children and adolescents. Pediatr Pulmonol. 1992, 12:240-246.
18. Tsoukias N.M., George S.C. A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol 1998, 85:653-666.
19. Tsoukias N.M., Shin H.W., Wilson A.F., George S.C. A single-breath technique with variable flow rate to characterize nitric oxide exchange dynamics in the lungs. J Appl Physiol 2001, 91:477-487.
20. Paraskakis E., Brindicci C., Fleming L., Krol R., Kharitonov S.A., Wilson N.M., Barnes P.J., Bush A. Measurement of Bronchial and Alveolar Nitric Oxide Production in Normal and Asthmatic Children. Am J Respir Crit Care Med. 2006, 174:260-267.
21. Cohen J., Douma W.R., ten Hacken N.H., Vonk J.M., Oudkerk M., Postma D.S. Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J. 2008, 31:1213-1220.
22. Moore W.C., Meyers D.A., Wenzel S.E., et al. Identification of asthma phenotypes using cluster analysis in the severe asthma program. Am J Respir Crit Care Med 2010, 181:315-323.
23. Bush A., Saglani S. Management of severe asthma in children. Lancet 2010, 376:814-825.
24. Bush A., Hedlin G., Carlsen K.H., de Benedictis F., Lodrup-Carlsen K., Wilson N. Severe childhood asthma: a common international approach? Lancet. 2008, 372:1019-1021.
25. Hedlin G., Bush A., Lodrup Carlsen K., et al. Problematic severe asthma in children, not one problem but many: a GA2LEN. Initiative. Eur Respir J 2010, 36:196-201. on behalf of the Problematic Severe Asthma in Childhood Initiative group.
26. Bracken M., Fleming L., Hall P., et al. The importance of nurse-led home visits in the assessment of children with problematic asthma. Arch Dis Child. 2009, 94:780-784.
27. Lødrup Carlsen K.C., Hedlin G., Bush A., et al. Assessment of problematic severe asthma in children. Eur Respir J. 2010 Oct 28, on behalf of the PSACI (Problematic Severe Asthma in Childhood Initiative) group, [Epub ahead of print].
28. Starosta V., Kitz R., Hartl D., Marcos V., Reinhardt D., Griese M. Bronchoalveolar pepsin, bile acids, oxidation, and inflammation in children with gastroesophageal reflux disease. Chest. 2007, 132:1557-1564.
29. Pavord I.D., Brightling C.E., Woltmann G., Wardlaw A.J. Non-eosinophilic corticosteroid unresponsive asthma. Lancet. 1999, 353:2213-2214.
30. Simpson J.L., Powell H., Boyle M.J., Scott R.J., Gibson P.G. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008, 177:148-155.
31. Amayasu H., Yoshida S., Ebana S., Yamamoto Y., Nishikawa T., Shoji T., Nakagawa H., Hasegawa H., Nakabayashi M., Ishizaki Y. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol. 2000, 84:594-598.
32. Yasui K., Agematsu K., Shinozaki K., Hokibara S., Nagumo H., Nakazawa T., Komiyama A. Theophylline induces neutrophil apoptosis through adenosine A2A receptor antagonism. J Leukoc Biol. 2000, 67:529-535.
33. Meagher L.C., Cousin J.M., Seckl J.R., Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol. 1996, 156:4422-4428.
34. Haldar P., Pavord I.D., Shaw D.E., et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008, 178:218-224.
35. Haldar P., Brightling C.E., Hargadon B., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009, 360:973-984.
36. Nair P., Pizzichini M.M., Kjarsgaard M., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009, 360:985-993.
37. Fleming LJ. The use of non-invasive markers of inflammation to guide therapy in children with severe asthma. MD Thesis, University of London, 2009.
38. Ito K., Chung K.F., Adcock I.M. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2006, 117:522-543.
39. Bacharier L.B., Strunk R.C., Mauger D., et al. Classifying asthma severity in children: mismatch between symptoms, medication use, and lung function. Am J Respir Crit Care Med 2004, 170:426-432.
40. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2007; 120 (Suppl): S94-138.
41. van Dalen C., Harding E., Parkin J., et al. Suitability of forced expiratory volume in 1 second/forced vital capacity vs percentage of predicted forced expiratory volume in 1 second for the classification of asthma severity in adolescents. Arch Pediatr Adolesc Med. 2008, 162:1169-1174.
42. Bossley C.J., Saglani S., Kavanagh C., et al. Corticosteroid responsiveness and clinical characteristics in childhood difficult asthma. Eur Respir J. 2009, 34:1052-1059.
43. Humbert M., Beasley R., Ayres J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60:309-316.
44. Massanari M., Milgrom H., Pollard S., et al. Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate--severe allergic asthma. Clin Pediatr (Phila). 2009, 48:859-865.
45. Lanier B., Bridges T., Kulus M., Taylor A.F., Berhane I., Vidaurre C.F. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009, 124:1210-1216.
46. Coren M.E., Rosenthal M., Bush A. The use of cyclosporin in corticosteroid dependent asthma. Arch Dis Child 1997, 77:522-523.
47. Bernstein I.L., Bernstein D.I., Dubb J.W., Faiferman I., Wallin B. A placebo-controlled multi-center study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial. J Allergy Clin Immunol 1996, 98:317-324.
48. Sole D., Costa-Carvalho B.T., Soares F.J., Rullo V.V., Naspitz C.K. Methotrexate in the treatment of corticodependent asthmatic children asthmatic children. J Invest Allergol Clin Immunol 1996, 6:126-130.
49. Johnston S.L., Pattemore P.K., Sanderson G., Smith S., Lampe F., Josephs L., Symington P., O'Toole S., Myint S.H., Tyrrell D.A., et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. Br Med J. 1995, 310:1225-1229.
50. Murray C.S., Poletti G., Kebadze T., Morris J., Woodcock A., Johnston S.L., Custovic A. Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children. Thorax. 2006, 61:376-382.
51. Ballester F., Soriano J.B., Otero I., et al. Asthma visits to emergency rooms and soybean unloading in the harbors of Valencia and A Coruña. Spain. Am J Epidemiol. 1999, 149:315-322.
52. Marks G.B., Colquhoun J.R., Girgis S.T., et al. Thunderstorm outflows preceding epidemics of asthma during spring and summer. Thorax. 2001, 56:468-471.
53. Haselkorn T., Fish J.E., Zeiger R.S., Szefler S.J., Miller D.P., Chipps B.E., Simons F.E., Weiss S.T., Wenzel S.E., Borish L., Bleecker E.R. Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol. 2009, 124. TENOR Study Group, 895-902.e1-4.
54. Haselkorn T., Zeiger R.S., Chipps B.E., Mink D.R., Szefler S.J., R Simons F.E., Massanari M., Fish J.E. Recent asthma exacerbations predict future exacerbations in children with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2009, 124:921-927.
55. Ayres J.G., Miles J.F., Barnes P.J. Brittle asthma. Thorax 1998, 53:315-321.
56. Bisgaard H., Le Roux P., Bjåmer D., Dymek A., Vermeulen J.H., Hultquist C. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 2006, 130:1733-1743.
57. O'Driscoll B.R., Powell G., Chew F., et al. Comparison of skin prick tests with specific immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy 2009, 39:1677-1683.
58. Denning D.W., O'Driscoll B.R., Powell G., et al. Randomized controlled trial of oral antifungal sensitization. The fungal asthma sensitization trial (FAST) study. Am J Respir Crit Care Med 2009, 179:11-18.
59. Vicencio A.G., Muzumdar H., Tsirilakis K., Kessel A., Nandalike K., Goldman D.L. Severe Asthma With Fungal Sensitization in a Child: Response to Itraconazole Therapy. Pediatrics. 2010 Apr 12, [Epub ahead of print].
60. De Wachter E., Vanbesien J., De Schutter I., Malfroot A., De Schepper J. Rapidly developing Cushing syndrome in a 4-year-old patient during combined treatment with itraconazole and inhaled budesonide. Eur J Pediatr. 2003, 162:488-489.